Work Here?
Overview
Remedy Robotics builds the Remedy N1 System, a remotely operable endovascular surgical robotics platform. It lets specialist physicians perform minimally invasive cardiovascular and neurointerventional procedures from any location by combining proprietary robotic hardware with AI-powered software. A portable console lets remote clinicians control multiple tools (guidewires, catheters, stents) inside catheterization labs, while AI fuses imaging data from CT, MRI, and fluoroscopy for real-time navigation. The company differentiates itself by enabling true teleoperation to overcome geographic care gaps, demonstrated by the world’s first fully remote neurointerventional procedures in humans across two hospitals. Its goal is to expand access to gold-standard endovascular treatments for millions of patients who currently lack timely specialist care, by scaling deployment in hospitals and enhancing its AI capabilities.
About Remedy Robotics
Industries
Data & Analytics
Robotics & Automation
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
Late Stage VC
Total Funding
$35M
Headquarters
San Francisco, California
Founded
2020
Get referred to Remedy Robotics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Hydrix signed a A$3.4 million N1 development contract on July 22, 2026.
- The Toronto first-in-human remote procedures validate hospital network deployment and bedside-team workflows.
- Mission Thrombectomy's 100-country network expands Remedy's clinical visibility and trial recruitment.
What critics are saying
- Remedy says the N1 remains under development and not yet available for sale.
- Pivotal clinical trials are still ahead in 2026, delaying revenue and adoption.
- Microbot Medical and XCath are building competing endovascular robotics platforms, pressuring Remedy's timeline.
What makes Remedy Robotics unique
- October 2025, Remedy completed fully remote neurointerventional procedures between Unity Health Toronto hospitals.
- Remedy N1 integrates remote catheter control with AI-guided imaging for endovascular workflows.
- SVIN Mission Thrombectomy named Remedy its exclusive robotics partner on October 30, 2025.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$35M
Above
Industry Average
Funded Over
1 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Company Equity
Paid Vacation
Commuter Benefits
Growth & Insights and Company News
6 month growth
↓ -12%1 year growth
↓ -8%2 year growth
↓ -12%Hydrix secures A$3.4 million medical Robotics development contract with US-based Remedy Robotics. Posted: 20th July 2026 ASX Announcement * Hydrix to support development of safety-critical software and embedded electronics for Remedy's next generation N1 robotic platform for endovascular intervention * The Contract reinforces Hydrix's position as a specialist engineering partner in advanced medical robotics, one of the fastest-growing segments of the global medical technology industry * According to Grand View Research, The US advanced medical Robotics market was valued at $3.84 billion in 2025, with projected 13.1% CAGR from 2026 to 2033 * Based on the agreed scope of work, to be undertaken on a time-and-materials basis, Hydrix expects the contract to generate approximately A$3.4 million in revenue. * Revenue will be recognised progressively in FY2027 and is >50% of Hydrix's current market capitalisation Hydrix Limited (ASX: HYD) (Hydrix) is pleased to announce it has secured a significant (A$3.4M) engineering development contract with US-based physical AI company Remedy Robotics. The agreement significantly expands Hydrix's existing multi-year relationship with Remedy Robotics and continues Hydrix's international expansion strategy focused on delivering mission-critical medical technologies, including advanced robotics, AI-enabled systems and Class II and III medical devices. Remedy Robotics is developing an AI-enabled robotic platform, the N1 System, for cardiovascular intervention, designed to enable experienced clinicians to perform complex endovascular procedures with increased precision and remotely over vast distances. Working with leading clinicians from around the world, including in Australia through its clinical partnership with the Australian Stroke Alliance, Remedy aims to radically expand access to specialist stroke and cardiovascular intervention regardless of patient location. Dr David Bell, Co-Founder and Chief Executive Officer, Remedy Robotics
In a landmark achievement that could redefine the future of healthcare, Remedy Robotics has successfully secured $35 million in funding. This monumental step is aimed at advancing their innovative …
Remedy Robotics has secured $35M to advance remote stroke treatment solutions. This funding aims to transform stroke care by overcoming geographical and logistical barriers, making it more accessible and efficient. Strokes are a major global health issue, being the second leading cause of death and third leading cause of disability. Traditional stroke treatment requires immediate intervention, which is often delayed, increasing the risk of long-term disability or death.
DCVC backs companies using deep tech to solve the biggest problems that matter. Our investments address climate change, human health, the operations of physically intensive industries, defense, security, space, and more.
Remedy Robotics is Hiring for 10 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Remedy Robotics
Industries
Data & Analytics
Robotics & Automation
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
Late Stage VC
Total Funding
$35M
Headquarters
San Francisco, California
Founded
2020
Remedy Robotics is Hiring for 10 Jobs on Simplify!
Find jobs on Simplify and start your career today